Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-4212 Ebola Vaccine Phase 1 Study
NCT02464670Phase 1Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- May 2015
- Primary completion
- May 2018
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of INO-4212 in Ebola virus disease (EVD), sponsored by Inovio Pharmaceuticals, Inc. Primary endpoint: Safety Assessment at 60 weeks. Started May 2015; status: completed.
02
Drugs
INO-4212
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02464670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02464670.